Published in final edited form as:

J Alzheimers Dis. 2018 ; 61(1): 91–101. doi:10.3233/JAD-170587.

Circulating progenitor cells correlate with memory, posterior cortical thickness and hippocampal perfusion

Daniel A. Nation, PhD^a, Alick Tan, PhD^b, Shubir Dutt, BA^a, Elissa C. McIntosh, MA^a, Belinda Yew, MA^a, Jean K. Ho, MA^a, Anna E. Blanken, MA^a, Jung Yun Jang, MA^a, Kathleen E. Rodgers, PhD^b, and Aimée Gaubert, BA^a

^aDepartment of Psychology, University of Southern California, Los Angeles, CA

^bDepartment of Clinical Pharmacy, University of Southern California, Los Angeles CA

Abstract

Background—Bone marrow-derived progenitor cells survey the vasculature and home to sites of tissue injury where they can promote repair and regeneration. It has been hypothesized that these cells may play a protective role neurodegenerative and vascular cognitive impairment.

Objective—To evaluate progenitor cell levels in older adults with and without mild cognitive impairment (MCI), and to relate circulating levels to memory, brain volume, white matter lesion volume and cerebral perfusion.

Method—Thirty-two older adults, free of stroke and cardiovascular disease, were recruited from the community and evaluated for diagnosis of MCI versus cognitively normal (CN). Participants underwent brain MRI and blood samples were taken to quantify progenitor reserve using flow cytometry (CD34+, CD34+CD133+ and CD34+CD133+CD309+ cells).

Results—Participants with MCI (n=10) exhibited depletion of all CPC markers relative to those who were CN (n=22), after controlling for age, sex and education. Post-hoc age, sex and education matched comparisons (n=10 MCI, n=10 CN) also revealed the same pattern of results. Depletion of CD34+ cells correlated with memory performance, left posterior cortical thickness and bilateral hippocampal perfusion. Participants exhibited low levels of vascular risk and white matter lesion burden that did not correlate with progenitor levels.

Conclusions—Circulating progenitor cells are associated with cognitive impairment, memory, cortical atrophy, and hippocampal perfusion. We hypothesize that progenitor depletion contributes to, or is triggered by, cognitive decline and cortical atrophy. Further study of progenitor cell depletion in older adults may benefit efforts to prevent or delay dementia.

Keywords

stem cells; cognitive dysfunction; memory; atrophy; perfusion

Address correspondence to: Daniel A. Nation, PhD, University of Southern California, 3620 South McClintock Avenue, Room 1010, Los Angeles, CA 90089, Phone: (213) 740-4503, Fax: (213) 746-9082, danation@usc.edu.

Disclosure statement

No competing financial interests exist.

INTRODUCTION

It is well established that vascular risk factors convey increased risk of cognitive decline in older adults [1]. Despite the role of vascular risk factors, very little is known about protective vascular factors in cognitive decline. One proposed mechanism of vascular protection involves circulating progenitor cells. Bone marrow-derived progenitor cells are frequently identified by expression of the hematopoietic stem cell marker, CD34, as well as the progenitor marker, CD133. Cells expressing both CD34 and CD133 are proangiogenic, and the subpopulation that also co-expresses CD309/VEGFR-2 (vascular endothelial growth factor receptor 2) represent endothelial progenitor cells, which have shown the ability to promote both angiogenesis and vasculogenesis [2, 3]. Collectively, these cells may promote brain health by homing to sites of cerebrovascular or neural injury and promoting angiogenesis and neurogenesis [4–11].

Despite the widely hypothesized role of these cells in protection against cerebrovascular and neural injury, very few human studies have investigated their potential role in age-related cognitive decline, dementia and aging brain health. One study using cell culture methods found that circulating angiogenic cells were depleted in Alzheimer's disease (AD) patients, where their number correlated with global indices of cognitive impairment [12]. Other studies have further supported the notion that proangiogenic cells (CD34+CD133+) are reduced in AD [13]. There is also evidence that CD34+ cells in general may be reduced in AD, where they correlate with amyloid beta levels in the cerebrospinal fluid (CSF) [14]. More recently, multiple progenitor cell markers correlated with better cognitive performance in a large non-clinical sample of employees at a major university [15]. To date, no studies have investigated progenitor cells in relation to memory ability in older adults or whether these cells are depleted in mild cognitive impairment (MCI). There have also been no studies investigating whether these circulating progenitor cells correlate with MRI-based measures of aging brain health, such as cortical thickness and white matter lesion (WML) burden. Although studies have linked CD34+ cell levels to improved cerebral blood flow after stroke [16], no studies have examined their role in perfusion changes associated with normal and pathological aging independent of stroke.

The present study sought to fill these knowledge gaps by investigating circulating progenitor cell levels in relation to cognitive function in a sample of community dwelling older adults, and to further study how these cells relate to MRI-based indicators of brain volume, white matter disease and cerebral perfusion.

METHOD

Participants and setting

Thirty-four participants were recruited from the community through word-of-mouth, flyers and community outreach events. All participants gave informed consent, and the study was approved by the University of Southern California (USC) Institutional Review Board (IRB). Study procedures were carried out in the Vascular Senescence and Cognition (VaSC) Laboratory, housed within the USC Department of Psychology. Participants were included if they were age 55 years or older and independently living with no history of clinical stroke,

dementia, learning disability, traumatic brain injury or other systemic or neurological illness or treatment that may impact central nervous system function. History of vascular risk factors was determined by clinical interview and objective measures, including blood pressure, body mass index (weight in kg / height in m²), dyslipidemia (history of elevated total cholesterol, low density lipoprotein cholesterol or triglycerides OR reduced high density cholesterol), diabetes (history of type I or II), history of cardiovascular disease (angina, intermittent claudication, myocardial infarction, stent placement, coronary artery bypass graft), or history of transient ischemic attack. Seated blood pressure was measured twice from each arm on two separate days (prior to neuropsychological testing for visit 1 and prior to MRI scan for visit 2), and systolic and diastolic pressures were averaged across these measures (pulse pressure was calculated as systolic minus diastolic pressure and mean arterial pressure was calculated as diastolic blood pressure plus one-third of the pulse pressure).

Two participants were excluded after clinical interview revealed additional factors that may impact progenitor cell function or neurocognition (one reported a history of human immunodeficiency virus and the other reported a family history of Huntington's disease). After these participants were excluded, 32 participants remained in study.

Blood draw and flow cytometry

Venipuncture was performed after an overnight fast on the morning before neuropsychological testing. Blood was drawn into K₃EDTA-coated tubes and 15 mL of anticoagulated whole blood was separated and diluted 1:1 with Dulbecco's Phosphate Buffered Saline (DPBS) + 2% fetal bovine serum (FBS). Diluted blood was overlaid on Histopaque-1077 (Sigma Aldrich). Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation according to manufacturer instructions, and washed twice with DPBS + 2% FBS at 120 x g for 10 min and 300 x g for 8 min at room temperature. PBMCs were counted on a hemacytometer. 1 million cells were transferred to an unstained tube blank, and the remainder was transferred to the stained tube where 5 µL of Human BD Fc Block (BD Biosciences) was added and incubated for 10–15 min. An additional 1 µL of each of the following antibodies were then added: (1) CD34-PE-Vio770 (clone: AC136, Miltenyi Biotec), (2) CD133-VioBright FITC (clone: AC133, Miltenyi Biotec), (3) PerCP/Cy5.5-CD309 (clone: 7D4-6, BioLegend). Tubes were incubated in the dark for 30 min at 4 °C. Samples were washed with 3 mL PBS, centrifuged at 300 x g for 8 min, and fixed with 2% formaldehyde in PBS until analysis. Compensation controls were conducted using AbC Total Antibody Compensation Bead Kit (ThermoFisher). Samples were acquired on a BD LSR II flow cytometer and analyzed on FlowJo software. Within the lymphocyte gate, positive gates for each marker were established over their fluorescence-minus-one bounds. Progenitor cell populations of interest included: CD34+, CD34+CD133+, and CD34+CD133+CD309+. Progenitor cell concentrations were calculated as a percentage of total cells within the lymphocyte gate.

APOE genotyping

APOE genotyping was conducted on the blood cell pellet fraction obtained from plasma separation. DNA was isolated from the pellet fraction using the PureLink Genomic DNA

Mini Kit (Thermo Fisher). Genotyping was conducted on isolated DNA using the TaqMan SNP Genotyping Assay (Thermo Fisher) on an Applied Biosystems 7300 Real Time PCR System. APOE gene SNPs were assessed for dbSNP IDs rs429358 and rs7412. Allelic discrimination was conducted using the included qPCR software. The APOE-ε4 allele was designated as rs429358-C + rs7412-C.

Neuropsychological testing and MCI diagnosis

After the venipuncture, participants were fed a light snack before undergoing comprehensive neuropsychological testing, including assessment of global cognition, memory, attention/executive function, language, and visuospatial abilities. The Mattis Dementia Rating Scale was used to screen participants for dementia (raw score > 126). Participants were classified as cognitively normal (CN) if they did not meet published neuropsychological criteria for MCI [17]. Specifically, MCI was diagnosed when participants scored >1 standard deviation below norm-referenced scores on >1 measure within a domain or >2 measures across domains. The neuropsychological battery used for diagnosis utilized 3 tests per domain of function (Supplemental Table 1). Numerous studies have previously established the validity of this neuropsychological approach to MCI and have shown improved stability [18], reduced false positive/negative rates [19, 20], and greater correlation with biomarkers of risk relative to other approaches [17].

Brain volumes and white matter lesions

A subset of participants (n=30 out of 32; 2 excluded due to MRI contraindications) returned within two weeks for a second visit to undergo structural MRI of the brain on a 3T Siemens Prisma magnet. All participants who were scanned underwent a T1-weighted magnetization prepared rapid gradient-echo (MPRAGE) sequence (Scan parameters: TR = 2300 ms, TE = 2.98 ms, TI = 900 ms, slice thickness = 1.20 mm, flip angle = 9°, field of view = 256 mm) for evaluation of brain volumes, and a subset of participants (n=25) also underwent T2-fluid attenuated inversion recovery (FLAIR) sequence (Scan parameters: TR = 10000 ms, TE = 91 ms, TI = 2500 ms, slice thickness = 5.0 mm, flip angle = 150°, field of view = 220 mm) for evaluation of white matter lesion (WML) volume.

For region-of-interest (ROI) analysis, post-processing of T1 scans was accomplished in FreeSurfer 5.3 using a semi-automated segmentation algorithm for quantification of bilateral hippocampal volumes (FreeSurfer 6.0), precuneus and posterior cingulate. Previous studies have detailed the specifics of FreeSurfer processing [21, 22]. After automated segmentation, each individual subject was checked for any inaccuracies or misclassifications; manual corrections were made as needed with FreeSurfer's built-in editing tools, cases were then re-processed, and resulting volumes were used for analyses.

White matter lesions were segmented with the lesion growth algorithm [23] implemented in the LST toolbox version 2.0.15 (www.statistical-modelling.de/lst.html) for SPM12 (Wellcome Department of Cognitive Neurology, London, UK; <http://www.fil.ion.ucl.ac.uk/spm/software/spm12>). An optimal initial threshold was determined via visual inspection, and manual quality control check ensured no gross over- or under-estimation.

For voxel-level indexing of cortical volume, voxel-based morphometry (VBM) analyses were conducted using SPM12, as previously described [24]. Briefly, T1-weighted images were segmented into grey and white matter tissue classes using SPM12's unified segmentation procedure, spatially normalized, and smoothed with an 8 mm full-width at half-maximum (FWHM) isotropic Gaussian kernel; the resulting grey matter images were checked for sample homogeneity to identify the presence of any potential outliers. Voxel-wise multiple regression was conducted with progenitor cell count as independent variable, grey matter map as dependent variable, and age, sex and total intracranial volume as covariates. As this was an exploratory analysis, we corrected for family-wise error in an initial analysis, but also conducted analyses with the cluster level significance threshold set at uncorrected $p < .001$.

Cerebral perfusion (arterial spin-labeling MRI)

Arterial spin-labeling (ASL)-MRI images were acquired on 28 participants using the Siemens PICORE-based pulsed ASL (PASL) sequence with the following parameters: TR = 3000 ms, TE = 12 ms, slice thickness = 4 mm, # of slices = 23, flip angle = 90°, field of view = 256 mm, TI1 = 700 ms, TI2 = 1900 ms, # of measurements = 105 (1 M0 image and 52 pairs of tag-control images), and total scan duration = 5:20. Images were processed with the ASLtbx Data Processing Toolbox (Ze Wang, University of Pennsylvania, <https://cfn.upenn.edu/~zewang/ASLtbx.php>) as implemented in SPM12 within MATLAB [25]. M0, ASL, and T1 images were first reoriented to ensure anterior commissure-posterior commissure alignment. ASL images were then motion corrected, coregistered to corresponding T1-weighted structural images, and spatially smoothed with a 6 mm FWHM isotropic Gaussian kernel. Pairwise tag-control subtractions resulted in 52 tag-control pairs, and these images were averaged to generate mean quantitative CBF maps, from which global mean perfusion (ml/100g/min) for each subject was calculated.

Mean CBF images were normalized to MNI template space for ROI analyses of regions including bilateral hippocampus and posterior cingulate. ROIs were selected and exported from the Automated Anatomical Labeling (AAL) atlas using the WFU PickAtlas Toolbox (ANSIR Lab, Wake Forest University School of Medicine, <http://fmri.wfubmc.edu/software/pickatlas>) in MATLAB [26]. Once ROIs were defined, mean CBF values were extracted for individual ROIs using the REX toolbox (Gabrieli Lab, Massachusetts Institute of Technology, <http://gablalab.mit.edu/index.php/news/95-gablalab-site/gablalab/people/swg/83>) in MATLAB.

Statistical analyses

Data were initially screened for outliers and departures from normality using indices of skewness and kurtosis. Log10-transformation was required to normalize the distribution of all progenitor cell counts and WML volumes.

Participant groups (CN vs. MCI) were compared on demographics and traditional vascular risk factors using independent sample *t*-tests and chi-square tests. Age, sex and vascular risk factors were also examined as potential contributors to progenitor cell counts. Progenitor cell counts were compared between groups using ANCOVA controlling for age, sex and

education level. Hierarchical multiple linear regression analyses examined relationships between progenitor cell counts and indicators of regional brain volume and perfusion in two regions previously implicated in cognitive decline: hippocampus and posterior cingulate. These limbic and cortical regions were selected due to their role in MCI and AD. Hierarchical regression models were also used to investigate progenitor cell counts in relation to WML volumes. For volumetric ROI and WML analyses, age, sex and total intracranial volume were used as covariates.

RESULTS

Demographics and vascular risk factors

Participants who were diagnosed with MCI were significantly older ($p = .02$) than those identified as CN, but did not otherwise differ on any demographic or vascular risk factor (Table 1). All participants were free of cardiovascular disease and stroke, and exhibited relatively low levels of vascular risk. There were no significant differences in progenitor cell counts between those with or without any of the traditional vascular risk factors, between men and women, or between APOE- $\epsilon 4$ carriers and non-carriers (all p 's $> .20$; Supplemental Table 2). There was also no significant correlation between any of the progenitor cell counts and age, body mass index, or any blood pressure measure (Supplemental Table 3).

Circulating progenitor cells in mild cognitive impairment

Relative to those identified as CN, participants meeting neuropsychological criteria for MCI exhibited attenuated circulating progenitor cells, including cells expressing CD34+, $F(1,27) = 6.053$, $p = .02$, $\eta^2 = .18$, CD34+CD133+, $F(1,27) = 7.007$, $p = .01$, $\eta^2 = .21$, and CD34+CD133+CD309+, $F(1,27) = 6.992$, $p = .01$, $\eta^2 = .21$, with medium-to-large effect sizes after correcting for age, sex and education (Figure 1). The same pattern of findings was replicated in univariate post-hoc analyses using an age-, sex- and education-matched subset of participants ($n = 10$ CN, $n = 10$ MCI), although CD34+CD133+CD309+ was no longer significant ($p = .056$) in this analysis (Supplemental Table 4).

Circulating progenitor cells and memory

After correcting for age, sex and education, analysis of progenitor cells levels in relation to memory function across the entire sample (CN and MCI combined) indicated that participants with greater CD34+ cell levels exhibited better immediate verbal memory ($p = .04$) and delayed verbal memory ($p = .02$), as well as immediate visual memory ($p < .001$) (Table 2A). Participants with greater circulating levels of CD34+CD133+ cells also exhibited better immediate visual memory, $R^2 = .18$, $\beta = .43$, $p = .001$. Finally, participants with higher levels of CD34+CD133+CD309+ cells showed better delayed verbal memory, $R^2 = .14$, $\beta = .39$, $p = .009$.

Circulating progenitor cells and MRI measures of cortical thickness and white matter lesions

In the subsample that underwent structural MRI ($n = 30$), ROI analyses indicated that higher circulating CD34+ cell counts were correlated with greater cortical thickness in the left posterior cingulate gyrus, after controlling for age, sex and total intracranial volume ($p = .$

006), but there was no significant association with right posterior cingulate volume or bilateral hippocampal volume (Table 2B). Parallel VBM analyses were not significant after family-wise error correction, but analyses using the uncorrected $p < .001$ cutoff confirmed that higher CD34+ cell counts correlated with greater cortical thickness within a significant cluster of left posterior brain regions, including the posterior cingulate, precuneus and lingual gyrus (Figure 2; top grey highlighted row in Table 3; Supplemental Figure 1).

Other progenitor cell counts (CD34+CD133+ and CD34+CD133+CD309+) did not show significant correlations with brain volumes in ROI analyses (all p 's $> .10$). There was also no significant relationship between progenitor cell counts and WML volume (CD34+: $R^2 = .001$, $\beta = .02$, $p = .90$; CD34+CD133+: $R^2 = .001$, $\beta = -.03$, $p = .85$; CD34+CD133+CD309+: $R^2 = .01$, $\beta = -.13$, $p = .45$).

Circulating progenitor cells and cerebral perfusion

In the subsample that underwent ASL-MRI ($n=27$), participants with lower CD34+ cell counts exhibited greater bilateral hippocampal perfusion, after controlling for age and sex, both p 's $< .05$ (Table 2C). There was no significant relationship with posterior cingulate perfusion, and other progenitor cell counts (CD34+CD133+ and CD34+CD133+CD309+) did not show significant correlations with brain perfusion (all p 's $> .10$).

DISCUSSION

The present study findings indicate that reduction of circulating progenitor cell in older adults is associated with worse memory function, diagnosis of MCI, thinning of posterior cortical regions and hyperperfusion of the bilateral hippocampus, all of which are indicators of pathological aging linked to increased risk of AD dementia. These findings are consistent with prior studies showing reduced CD34+ cells in dementia patients relative to normally aging controls [14], but further suggest that CD34+ cell loss may be related to early risk indicators rather than the mere product of advanced neurodegeneration. Although causality cannot be concluded from this observational study, the findings provide convergent support for an association between progenitor cell levels and multiple dementia risk factors. We hypothesize that progenitor cells may play a potentially protective role in aging brain health and could represent valuable therapeutic targets in prevention trials, but much more research is needed to determine whether the observed associations in the present study are causal in nature. The current study evaluated only cross-sectional associations. Assessment of progenitor cell levels in relation to longitudinal decline in cognition and brain health will allow examination of the potential for progenitor cell levels as an early risk indicator. Future studies will employ logistic regression and other predictive modeling methods to determine whether progenitor cell counts may be of value in identifying those at risk for progressive cognitive decline and dementia.

Our MCI sample was significantly older than the CN group, but there was no significant relationship between age and progenitor cell levels, and post-hoc analysis of an age-matched sample revealed a similar pattern of findings, suggesting that demographic factors alone cannot account for the observed attenuation of progenitor cells in MCI. Prior studies have shown that CD34+ cells correlate with performance on global cognitive screening measures

among dementia patients [13, 27]. The present study extends these findings to non-demented older adults with low vascular risk, where progenitor cell levels correlated with neuropsychological tests of memory across the entire sample. Insidious memory decline is characteristic of the earliest stages of AD, and may be detectable even in older adults with normal range cognitive function [28]. The observed relationship between progenitor cell levels and memory function raises the possibility that progenitor depletion may contribute to the earliest stages of cognitive decline in patients at risk for AD dementia, although the relevance of progenitor cells to AD cannot be inferred from the present study of non-demented older adults.

Prior studies have been mixed with regard to the role of circulating progenitor cells in Alzheimer's versus vascular cognitive impairment [13, 14, 27]. The present study did not include assessment of AD biomarkers, limiting conclusions regarding etiological factors, but the study sample was deliberately selected to be low in vascular risk burden. No participants reported a known history of cardiovascular disease or stroke and the level of WML burden was correspondingly low. We also noted that circulating progenitor cell levels were not associated with vascular risk factors or WML volume, and vascular risk burden did not differ between CN and MCI participants. However, we note that the limited sample size does not allow us to rule out significant associations between vascular risk and progenitor cell levels in the general population. Worse memory performance, diagnosis of MCI and thinning of posterior cingulate cortex are all characteristic of the early stages of AD [29–32]. This is consistent with prior studies indicating that CD34+ cells are depleted in dementia due to AD, where they correlate with global impairment and CSF amyloid beta levels [13, 14].

Animal studies have demonstrated that circulating progenitor cells may be derived from the bone marrow [33], but can also mobilize to the brain and differentiate into neural tissues [11, 34] or promote neurogenesis indirectly through paracrine growth factor signaling [10, 35]. Alternatively, these cells may help clear excess amyloid beta by differentiating into macrophages, microglia or astrocytes [11, 36–38]. The subset of CD34+ cells with proangiogenic capability, including CD133+ and CD309+ cells, may also promote neurovascular unit function [39], which is compromised early in the AD process [40, 41]. The present study found that although CD34+CD133+ and CD34+CD133+CD309+ cells were attenuated in MCI and showed some correlation with memory function, they did not relate to brain volume, perfusion or WML burden. This could be due to the nature of our low vascular risk sample, as these markers may have greater relevance to vascular disease.

Prior studies have indicated that circulating CD34+ cell levels are associated with greater cerebral perfusion in stroke patients [16], suggesting that improved cerebral perfusion may be one mechanism by which CD34+ cells could benefit cognitive function. The present study found that older adults with lower CD34+ cells actually exhibited *greater* hippocampal perfusion. This finding is consistent with several prior studies demonstrating hippocampal hyperperfusion in CN older adults at genetic risk for AD [42], those with subtle memory decline [43] and in MCI [44]. Based on these studies, a biphasic model has been hypothesized in which early compensatory changes in neurovascular function lead to an initial hyperperfusion of the hippocampus followed by an eventual decline in perfusion after the onset of AD dementia [45]. Thus, the inverse correlation between CD34+ cell levels and

hippocampal perfusion is consistent with the notion that lower CD34+ cell counts are associated with AD risk factors. Post-mortem studies in human bone marrow transplant patients demonstrate that progenitor cells migrate to the hippocampus where they undergo transdifferentiation into neurons, astrocytes and microglia, specifically within hippocampal regions implicated in adult neurogenesis [11], although this mechanism is highly controversial. The hippocampus and posterior cingulate are highly interconnected structures that play critical roles in memory function and are implicated in AD dementia [46]. Thus, the observed correlations suggest a relationship between CD34+ cell levels and both structural and functional markers in these regions, as well as memory performance. We hypothesize that CD34+ cells may be playing a supportive role in memory system function in older adults at risk of AD dementia.

It remains unclear whether progenitor cell depletion is a contributing cause or downstream consequence of neuropathology. In the context of chronic tissue inflammation, circulating progenitor cell levels may attenuate as these cells migrate to and are sequestered within sites of injury, where they may undergo terminal differentiation and lose their regenerative capacity [47]. However, progenitor cells may also be mobilized by tissue injury and other pathogenic factors [48]. For example, in a study relating CD34+ cell counts to CSF amyloid beta levels, AD patients had reduced CD34+ cells relative to controls, yet there was an inverse relationship between CD34+ cell counts and CSF amyloid beta [14], suggesting that higher CD34+ counts were related to greater cerebral retention of amyloid beta [49]. These complexities may partly explain the mixed findings regarding whether CD34+ cell counts are increased or decreased in more advanced AD dementia patients versus controls [13, 14, 50–52].

The present study addresses some of these questions from the prior literature by investigating progenitor cell counts during the earlier, MCI stage of cognitive decline in a sample with low levels of vascular risk. The use of a community-based sample with actuarial criteria for MCI is another study strength relative to prior findings comparing memory clinic-based samples to normal volunteers. The present study is also the first to investigate progenitor cell correlations with neuropsychological measures of memory and MRI-based indicators of brain volume and perfusion. Findings are consistent with the progenitor reserve hypothesis, which states that circulating progenitor cells may help buffer cognitive decline in the context of neuropathology [53, 54]. Thus, it is possible that having lower levels of progenitor reserve increases the risk of dementia, but it is also possible that progenitor cells are depleted from circulation during the early stages of disease due to migration and sequestration at sites of neuronal and cerebrovascular injury. Further studies utilizing longitudinal design and *in vivo* markers of AD pathophysiology are needed to better establish how progenitor cells may relate to disease progression and clinical manifestation. Future studies in animal models may also examine how tissue migration and progenitor cell fate interact with disease processes to shed further light on potential mechanisms that could mediate an hypothesized protective benefit of progenitor cell reserve.

Prior animal studies have found that granulocyte macrophage colony stimulating factor (GM-CSF) and other factors that stimulate mobilization of progenitor cells are critically involved in learning, memory and synapse formation and maintenance [4, 55, 56]. Thus,

pharmacological manipulation of circulating progenitor cells through GM-CSF analogues may have therapeutic potential. Direct progenitor cell transplantation has also been successfully applied to coronary artery disease in clinical trials [57], suggesting potential for multiple therapeutic modalities. Clinical trials in AD dementia patient samples using GM-CSF analogues are underway, but these trials may fail due to treatment initiation during a late stage of neurodegeneration after the emergence of frank dementia. The current study suggests that the focus of these trials shift to the MCI phase of disease when secondary prevention options may provide a greater benefit with regard to risk of progression to dementia.

The present study findings are observational in nature, but they support a relationship between greater progenitor cell reserve and decreased risk factors for dementia. It has been hypothesized that early intervention to increase circulating progenitor cell levels could reduce dementia risk by supporting cerebrovascular and neuronal function. Future studies further examining the potential protective impact of circulating progenitor cells are warranted. Additionally, further studies are needed to explore other specific progenitor subpopulations in an effort to identify specific cell-types and regulatory factors that may be relevant to cognitive decline.

The present study is not without limitations in that it was small and cross-sectional. We did not employ multiple comparison corrections due to the exploratory nature of the study, and we did not have sufficient power for our voxel-level findings to survive family-wise error correction. Age and APOE-ε4 differences between cognitively normal and MCI groups may have confounded study findings, although matched comparisons showed a similar pattern of results. Despite these caveats, the study findings contribute substantially to our currently very limited understanding of the relationship between progenitor cells and both aging brain health and dementia risk factors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The present study was supported by National Institutes of Health (NIH) grants (R21 AG055034, P50 AG005142 and P01 AG052350).

References

1. Polidori MC, Pientka L, Mecocci P. A review of the major vascular risk factors related to Alzheimer's disease. *J Alzheimers Dis.* 2012; 32:521–530. [PubMed: 22836188]
2. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. *Blood.* 2000; 95:952–958. [PubMed: 10648408]
3. Herrmann M, Binder A, Menzel U, Zeiter S, Alini M, Verrier S. CD34/CD133 enriched bone marrow progenitor cells promote neovascularization of tissue engineered constructs in vivo. *Stem Cell Res.* 2014; 13:465–477. [PubMed: 25460607]

4. Wang P, Xie ZH, Guo YJ, Zhao CP, Jiang H, Song Y, Zhu ZY, Lai C, Xu SL, Bi JZ. VEGF-induced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease. *Biochem Biophys Res Commun*. 2011; 411:620–626. [PubMed: 21771586]
5. Hao Q, Su H, Palmer D, Sun B, Gao P, Yang GY, Young WL. Bone marrow-derived cells contribute to vascular endothelial growth factor-induced angiogenesis in the adult mouse brain by supplying matrix metalloproteinase-9. *Stroke*. 2011; 42:453–458. [PubMed: 21164138]
6. Szmítko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S. Endothelial progenitor cells: new hope for a broken heart. *Circulation*. 2003; 107:3093–3100. [PubMed: 12821589]
7. Simard T, Jung RG, Motazedian P, Di Santo P, Ramirez FD, Russo JJ, Labinaz A, Yousef A, Anantharam B, Pourdjabbar A, Hibbert B. Progenitor Cells for Arterial Repair: Incremental Advancements towards Therapeutic Reality. *Stem Cells Int*. 2017; 2017:8270498. [PubMed: 28232850]
8. Basile DP, Yoder MC. Circulating and tissue resident endothelial progenitor cells. *J Cell Physiol*. 2014; 229:10–16. [PubMed: 23794280]
9. Fan Y, Shen F, Frenzel T, Zhu W, Ye J, Liu J, Chen Y, Su H, Young WL, Yang GY. Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. *Ann Neurol*. 2010; 67:488–497. [PubMed: 20437584]
10. Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, Vincent P, Pumiglia K, Temple S. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. *Science*. 2004; 304:1338–1340. [PubMed: 15060285]
11. Cogle CR, Yachnis AT, Laywell ED, Zander DS, Wingard JR, Steindler DA, Scott EW. Bone marrow transdifferentiation in brain after transplantation: a retrospective study. *Lancet*. 2004; 363:1432–1437. [PubMed: 15121406]
12. Lee ST, Chu K, Jung KH, Park HK, Kim DH, Bahn JJ, Kim JH, Oh MJ, Lee SK, Kim M, Roh JK. Reduced circulating angiogenic cells in Alzheimer disease. *Neurology*. 2009; 72:1858–1863. [PubMed: 19470969]
13. Kong XD, Zhang Y, Liu L, Sun N, Zhang MY, Zhang JN. Endothelial progenitor cells with Alzheimer's disease. *Chin Med J (Engl)*. 2011; 124:901–906. [PubMed: 21518600]
14. Maler JM, Spitzer P, Lewczuk P, Kornhuber J, Herrmann M, Wiltfang J. Decreased circulating CD34+ stem cells in early Alzheimer's disease: Evidence for a deficient hematopoietic brain support? *Mol Psychiatry*. 2006; 11:1113–1115. [PubMed: 17033629]
15. Hajjar I, Goldstein FC, Waller EK, Moss LD, Quyyumi A. Circulating Progenitor Cells is Linked to Cognitive Decline in Healthy Adults. *Am J Med Sci*. 2016; 351:147–152. [PubMed: 26897269]
16. Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K, Nagatsuka K, Todo K, Mori K, Stern DM, Soma T, Naritomi H. Circulating CD34-positive cells provide an index of cerebrovascular function. *Circulation*. 2004; 109:2972–2975. [PubMed: 15184275]
17. Bondi MW, Edmonds EC, Jak AJ, Clark LR, Delano-Wood L, McDonald CR, Nation DA, Libon DJ, Au R, Galasko D, Salmon DP. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. *J Alzheimers Dis*. 2014; 42:275–289. [PubMed: 24844687]
18. Jak AJ, Bondi MW, Delano-Wood L, Wierenga C, Corey-Bloom J, Salmon DP, Delis DC. Quantification of five neuropsychological approaches to defining mild cognitive impairment. *Am J Geriatr Psychiatry*. 2009; 17:368–375. [PubMed: 19390294]
19. Edmonds EC, Delano-Wood L, Clark LR, Jak AJ, Nation DA, McDonald CR, Libon DJ, Au R, Galasko D, Salmon DP, Bondi MW. Alzheimer's Disease Neuroimaging I. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. *Alzheimers Dement*. 2015; 11:415–424. [PubMed: 24857234]
20. Edmonds EC, Delano-Wood L, Jak AJ, Galasko DR, Salmon DP, Bondi MW. Alzheimer's Disease Neuroimaging I. "Missed" Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria. *J Alzheimers Dis*. 2016; 52:685–691. [PubMed: 27031477]
21. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. *Neuroimage*. 1999; 9:179–194. [PubMed: 9931268]
22. Segonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, Fischl B. A hybrid approach to the skull stripping problem in MRI. *Neuroimage*. 2004; 22:1060–1075. [PubMed: 15219578]

23. Schmidt P, Gaser C, Arsic M, Buck D, Forschler A, Berthele A, Hoshi M, Ilg R, Schmid VJ, Zimmer C, Hemmer B, Muhlau M. An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. *Neuroimage*. 2012; 59:3774–3783. [PubMed: 22119648]
24. Ashburner J, Friston KJ. Unified segmentation. *Neuroimage*. 2005; 26:839–851. [PubMed: 15955494]
25. Wang Z, Aguirre GK, Rao H, Wang J, Fernandez-Seara MA, Childress AR, Detre JA. Empirical optimization of ASL data analysis using an ASL data processing toolbox: ASLtbx. *Magn Reson Imaging*. 2008; 26:261–269. [PubMed: 17826940]
26. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage*. 2002; 15:273–289. [PubMed: 11771995]
27. Taguchi A, Matsuyama T, Nakagomi T, Shimizu Y, Fukunaga R, Tatsumi Y, Yoshikawa H, Kikuchi-Taura A, Soma T, Moriwaki H, Nagatsuka K, Stern DM, Naritomi H. Circulating CD34-positive cells provide a marker of vascular risk associated with cognitive impairment. *J Cereb Blood Flow Metab*. 2008; 28:445–449. [PubMed: 17684516]
28. Duke Han S, Nguyen CP, Stricker NH, Nation DA. Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis. *Neuropsychol Rev*. 2017
29. Bondi MW, Jak AJ, Delano-Wood L, Jacobson MW, Delis DC, Salmon DP. Neuropsychological contributions to the early identification of Alzheimer's disease. *Neuropsychol Rev*. 2008; 18:73–90. [PubMed: 18347989]
30. Spulber G, Niskanen E, Macdonald S, Kivipelto M, Padilla DF, Julkunen V, Hallikainen M, Vanninen R, Wahlund LO, Soininen H. Evolution of global and local grey matter atrophy on serial MRI scans during the progression from MCI to AD. *Curr Alzheimer Res*. 2012; 9:516–524. [PubMed: 22191564]
31. Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. *Neuroimage*. 2009; 47:1196–1206. [PubMed: 19463961]
32. Wirth M, Pichet Binette A, Brunecker P, Kobe T, Witte AV, Floel A. Divergent regional patterns of cerebral hypoperfusion and gray matter atrophy in mild cognitive impairment patients. *J Cereb Blood Flow Metab*. 2017; 37:814–824. [PubMed: 27037094]
33. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. *Science*. 2002; 298:601–604. [PubMed: 12228721]
34. Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. *Science*. 2000; 290:1779–1782. [PubMed: 11099419]
35. Majka M, Janowska-Wieczorek A, Ratajczak J, Ehrenman K, Pietrzkowski Z, Kowalska MA, Gewirtz AM, Emerson SG, Ratajczak MZ. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. *Blood*. 2001; 97:3075–3085. [PubMed: 11342433]
36. Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, Inlay MA, Poon WW, Blurton-Jones M. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. *Proc Natl Acad Sci U S A*. 2016; 113:E1316–1325. [PubMed: 26884167]
37. Nedergaard M. Neuroscience. Garbage truck of the brain. *Science*. 2013; 340:1529–1530. [PubMed: 23812703]
38. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. *Neuron*. 2006; 49:489–502. [PubMed: 16476660]
39. Malinovskaya NA, Komleva YK, Salmin VV, Morgun AV, Shuvaev AN, Panina YA, Boitsova EB, Salmina AB. Endothelial Progenitor Cells Physiology and Metabolic Plasticity in Brain Angiogenesis and Blood-Brain Barrier Modeling. *Front Physiol*. 2016; 7:599. [PubMed: 27990124]

40. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nat Rev Neurosci.* 2011; 12:723–738. [PubMed: 22048062]
41. Montagne A, Nation DA, Pa J, Sweeney MD, Toga AW, Zlokovic BV. Brain imaging of neurovascular dysfunction in Alzheimer's disease. *Acta Neuropathol.* 2016; 131:687–707. [PubMed: 27038189]
42. Fleisher AS, Podraza KM, Bangen KJ, Taylor C, Sherzai A, Sidhar K, Liu TT, Dale AM, Buxton RB. Cerebral perfusion and oxygenation differences in Alzheimer's disease risk. *Neurobiol Aging.* 2009; 30:1737–1748. [PubMed: 18325636]
43. Bangen KJ, Clark A, Edmonds E, Evangelista N, Werhane M, Thomas K, Locano L, Tran M, Zlatar ZZ, Nation DA, Bondi MW, Delano-Wood L. Cerebral blood flow and amyloid- β interact to affect memory performance in cognitively normal older adults. *Frontiers in Aging Neuroscience.* 2017
44. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM. Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging. *Radiology.* 2009; 250:856–866. [PubMed: 19164119]
45. Wierenga CE, Hays CC, Zlatar ZZ. Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease. *J Alzheimers Dis.* 2014; 42(Suppl 4):S411–419. [PubMed: 25159672]
46. Zhou Y, Dougherty JH Jr, Hubner KF, Bai B, Cannon RL, Hutson RK. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. *Alzheimers Dement.* 2008; 4:265–270. [PubMed: 18631977]
47. Pietras EM, Mirantes-Barbeito C, Fong S, Loeffler D, Kovtonyuk LV, Zhang S, Lakshminarasimhan R, Chin CP, Techner JM, Will B, Nerlov C, Steidl U, Manz MG, Schroeder T, Passegue E. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. *Nat Cell Biol.* 2016; 18:607–618. [PubMed: 27111842]
48. Massot A, Navarro-Sobrinho M, Penalba A, Arenillas JF, Giralt D, Ribo M, Molina CA, Alvarez-Sabin J, Montaner J, Rosell A. Decreased levels of angiogenic growth factors in intracranial atherosclerotic disease despite severity-related increase in endothelial progenitor cell counts. *Cerebrovasc Dis.* 2013; 35:81–88. [PubMed: 23429001]
49. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. *Alzheimers Dement.* 2015; 11:58–69. [PubMed: 24795085]
50. Bigalke B, Schreitmuller B, Sopova K, Paul A, Stransky E, Gawaz M, Stellos K, Laske C. Adipocytokines and CD34 progenitor cells in Alzheimer's disease. *PLoS One.* 2011; 6:e20286. [PubMed: 21633502]
51. Breining A, Silvestre JS, Dieudonne B, Vilar J, Faucounau V, Verny M, Neri C, Boulanger CM, Boddaert J. Biomarkers of vascular dysfunction and cognitive decline in patients with Alzheimer's disease: no evidence for association in elderly subjects. *Aging Clin Exp Res.* 2016; 28:1133–1141. [PubMed: 26803509]
52. Stellos K, Panagiota V, Sachsenmaier S, Trunk T, Straten G, Leyhe T, Seizer P, Geisler T, Gawaz M, Laske C. Increased circulating progenitor cells in Alzheimer's disease patients with moderate to severe dementia: evidence for vascular repair and tissue regeneration? *J Alzheimers Dis.* 2010; 19:591–600. [PubMed: 20110604]
53. Wu CC, Wang IF, Chiang PM, Wang LC, Shen CJ, Tsai KJ. G-CSF-mobilized Bone Marrow Mesenchymal Stem Cells Replenish Neural Lineages in Alzheimer's Disease Mice via CXCR4/SDF-1 Chemotaxis. *Mol Neurobiol.* 2016
54. Lampron A, Pimentel-Coelho PM, Rivest S. Migration of bone marrow-derived cells into the central nervous system in models of neurodegeneration. *J Comp Neurol.* 2013; 521:3863–3876. [PubMed: 23682015]
55. Krieger M, Both M, Kranig SA, Pitzer C, Klugmann M, Vogt G, Draguhn A, Schneider A. The hematopoietic cytokine granulocyte-macrophage colony stimulating factor is important for cognitive functions. *Sci Rep.* 2012; 2:697. [PubMed: 23019518]

56. Prakash A, Medhi B, Chopra K. Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-beta induced experimental model of Alzheimer's disease. *Pharmacol Biochem Behav.* 2013; 110:46–57. [PubMed: 23756182]
57. George JC. Stem cell therapy in acute myocardial infarction: a review of clinical trials. *Transl Res.* 2010; 155:10–19. [PubMed: 20004357]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1. Progenitor cell counts are attenuated in MCI relative to normal aging

Circulating progenitor cell levels were attenuated in older adults with MCI relative to those who were CN, $*p < .05$.

Figure 2. VBM analysis: CD34+ cell counts correlate with grey matter volume in posterior regions

Overlaid t -map is the result of voxel-wise multiple regression with CD34+ cell count as independent variable, grey matter volume as dependent variable, and age, sex, and total intracranial volume as covariates of no interest. Map is thresholded at cluster-level uncorrected $p < 0.001$. Minimum and maximum t -scores are displayed on the color bar.

Table 1

Demographics and clinical characteristics of the sample.

Demographics N	CN 22	MCI 10	<i>p</i>-value
Age, yrs	69.0 (6.8)	75.8 (8.1)	.02
Sex, % male	31.8%	60.0%	.13
Education, yrs	16.0 (2.2)	15.2 (4.0)	.47
APOE-ε4 carriers	14.3%	25.0%	.50
Vascular Risk Factors			
Dyslipidemia % (n)	63.6%	60.0%	.84
Diabetes % (n)	9.1%	10%	.90
Smoking History or Current % (n)	22.7%	50.0%	.12
Transient Ischemic Attack % (n)	4.5%	0%	.49
Systolic Blood Pressure (mmHg)	128.0 (12.8)	130.5 (14.2)	.64
Diastolic Blood Pressure (mmHg)	76.5 (9.3)	76.7 (9.6)	.94
Mean Arterial Pressure (mmHg)	93.7 (9.9)	94.7 (9.2)	.80
Pulse Pressure (mmHg)	51.5 (7.9)	53.7 (14.1)	.58
Body Mass Index (kg/m ²)	26.7 (5.8)	26.4 (5.6)	.89

Table 2

CD34+ cell count correlates with memory, brain volume and perfusion.

A. Memory		R²	β	p-value
<i>WMS-IV Verbal Memory</i>	<i>LM I</i>	.10	.35	.04
	<i>LM II</i>	.12	.38	.02
<i>WMS-IV Visual Memory</i>	<i>VR I</i>	.27	.58	<.001
	<i>VR II</i>	.15	.43	.006
B. Brain Volume				
<i>Hippocampal Volume</i>	<i>Left</i>	.01	.11	.59
	<i>Right</i>	.001	.04	.82
<i>Posterior Cingulate Thickness</i>	<i>Left</i>	.25	.55	.006
	<i>Right</i>	.008	.10	.59
C. Brain Perfusion				
<i>Hippocampal Perfusion</i>	<i>Left</i>	.15	-.42	.048
	<i>Right</i>	.19	-.47	.025
<i>Posterior Cingulate Perfusion</i>	<i>Left</i>	.03	.18	.35
	<i>Right</i>	.002	.05	.78

Table 3

CD34+ significant clusters in VBM analysis

cluster (voxels)	cluster (p)	peak (T)	peak (Z)	peak (p)	x	y	z
429	0.022	5.85	4.6	<0.001	-6	-54	3
66	0.335	4.77	3.98	<0.001	51	-22	10
46	0.423	4.13	3.57	<0.001	40	-34	44
20	0.61	4.13	3.57	<0.001	-14	-60	48
17	0.642	3.85	3.38	<0.001	63	-14	12
63	0.346	3.81	3.35	<0.001	60	8	-12
22	0.591	3.75	3.31	<0.001	6	-56	-4
20	0.61	3.68	3.25	0.001	60	-2	2
11	0.718	3.67	3.25	0.001	-56	8	20
5	0.822	3.67	3.25	0.001	-16	48	-24
3	0.87	3.6	3.2	0.001	66	-2	22
4	0.845	3.59	3.19	0.001	8	-69	-28
3	0.87	3.57	3.18	0.001	-54	-14	9
3	0.87	3.54	3.15	0.001	56	15	-28
7	0.782	3.49	3.12	0.001	-46	-56	-34
1	0.935	3.46	3.1	0.001	30	48	20
2	0.899	3.46	3.1	0.001	48	-15	2